Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic...

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Platinum-based chemotherapy is standard for advanced non-small cell lung cancer (NSCLC) but resistance is common.
• Previous second-line treatments like pemetrexed, docetaxel, erlotinib, and gefitinib have not improved overall survival.
• Targeted therapies combined with existing treatments have also failed to enhance survival outcomes.

Purpose of the Study:

• To review the efficacy of second-line therapies for non-small cell lung cancer (NSCLC) after initial platinum-based chemotherapy failure.
• To highlight the emergence of immune checkpoint inhibitors as a new standard of care.

Main Methods:

• Review of randomized trials evaluating second-line treatments for NSCLC.
• Comparison of outcomes between novel monoclonal antibodies targeting PD-1/PD-L1 and standard chemotherapy.
• Analysis of survival data from clinical trials.

Main Results:

• Novel monoclonal antibodies targeting the programmed cell death 1 (PD-1) or PD-L1 pathway demonstrated significant improvements in overall survival compared to standard chemotherapy.
• Nivolumab and pembrolizumab are now considered standard second-line therapies for NSCLC patients.
• Atezolizumab also shows promise in this patient population.

Conclusions:

• Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway represent a significant advancement in second-line treatment for NSCLC.
• These therapies offer improved survival outcomes for patients who progress on or after platinum-based chemotherapy.
• Further investigation and application of atezolizumab are warranted.